ストックスクリーナーアプリを入手
0.6301
0.62%
-0.0039
アフターアワーズ：
.62
-0.0101
-1.60%
前日終値:
$0.634
開ける：
$0.64
24時間の取引高:
7.72M
Relative Volume:
1.20
時価総額：
$26.18M
収益：
-
当期純損益:
$-22.83M
株価収益率:
-0.7327
EPS:
-0.86
ネットキャッシュフロー:
$-20.87M
1週間 パフォーマンス:
+31.82%
1か月 パフォーマンス:
+43.20%
6か月 パフォーマンス:
-69.11%
1年 パフォーマンス:
-62.27%
1日の値動き範囲:
$0.58
$0.6775
1週間の範囲:
$0.425
$1.29
52週間の値動き範囲:
$0.34
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
名前
Cognition Therapeutics Inc
セクター
電話
412-481-2210
住所
2403 SIDNEY STREET, PITTSBURGH
CGTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.6301 | 26.18M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 開始されました | B. Riley Securities | Buy |
| 2021-11-03 | 開始されました | Oppenheimer | Outperform |
Cognition Therapeutics Inc (CGTX) 最新ニュース
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial - Nasdaq
Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely - Simply Wall St
This Biotech Is Already Off To The Races Before The Opening Bell - MSN
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data - Yahoo Finance
Cognition Therapeutics Reveals Encouraging Results from Phase 2 COG1201 SHIMMER Study - Defense World
B. Riley Securities Upgrades Cognition Therapeutics (CGTX) - MSN
Cognition Therapeutics announces results in Phase 2 study of CT1812 - Yahoo Finance
Enhanced Cognition: Lewy body dementia phase II pumps stock - BioWorld Online
S&P 500 Health Care [Sector] (SRHC) QuotePress Release - The Globe and Mail
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? - Benzinga
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com
Cognition Therapeutics Hopes To Affirm CT1812 Holds The Key To Slowing Progression Of Dementia With Lewy Bodies - Nasdaq
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 - MSN
Cognition-Enhancing Drugs Market Innovations and Key Players: - openPR
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Yahoo Finance
HC Wainwright Has Negative Outlook of CGTX FY2024 Earnings - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Consensus Price Target from Analysts - Defense World
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
HC Wainwright Reiterates “Buy” Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
What is B. Riley’s Estimate for CGTX FY2024 Earnings? - Defense World
Head to Head Comparison: Inhibrx (NASDAQ:INBX) and Cognition Therapeutics (NASDAQ:CGTX) - Defense World
What is B. Riley’s Estimate for CGTX FY2025 Earnings? - Defense World
Cognition Therapeutics concludes Phase 2 DLB study By Investing.com - Investing.com Canada
Cognition Therapeutics Announces all Participants have - GlobeNewswire
Cognition Therapeutics concludes Phase 2 DLB study - Investing.com
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis - Yahoo Finance
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population - GlobeNewswire
Cognition's Alzheimer's Drug Shows 95% Reduction in Cognitive Decline in Phase 2 Trial - StockTitan
An understudied dementia soon to get a pair of Phase II readouts - BioCentury
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Life Sciences Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Cognition Therapeutics Inc Reports Q3 2024 GAAP EPS of $(0.25), Missing Estimates; Net Loss Widens to $9.9 Million - GuruFocus.com
Cognition Therapeutics Reports Promising Q3 2024 Results - TipRanks
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - Yahoo Finance
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum - The Manila Times
Cognition Therapeutics CEO to Present Alzheimer's Drug Study Results at Zacks Forum - StockTitan
Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $8.00 - Defense World
Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients - Genetic Engineering & Biotechnology News
Cognition Therapeutics stock rated Buy, target held amid CT1812 data By Investing.com - Investing.com UK
November’s Small-Cap Treasures: 3 Stocks Poised for Growth - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from Chardan Capital - Defense World
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD - The Manila Times
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with - The Bakersfield Californian
Global Neurological Biomarkers Market to Surpass USD 16 Billion Mark by 2030 | DelveInsight - PR Newswire
Cognition Therapeutics Inc (CGTX) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):